Validation of Prostate Cancer Risk Variants by CRISPR/Cas9 Mediated Genome Editing

Xing Wang[1], James E. Hayes[1,2,3], Xing Xu[2,3], Xiaoni Gao[1,2], Dipti Mehta[4], Hans G. Lilja[4,5,6], *Robert J. Klein[1,2]

[1]Department of Genetics and Genomic Sciences and Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY
[2]Program in Cancer Biology and Genetics and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
[3]Graduate School of Biomedical Sciences, Weill Cornell Medical College, New York, NY
[4]Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
[5]Departments of Laboratory Medicine and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
[6]Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK and Department of Translational Medicine, Lund University, Malmö, Sweden

* To whom correspondence should be addressed. Tel: +1 212 824 8949 Fax: +1 646 537 8660; Email: robert.klein@mssm.edu

Present Address: Xing Xu, SolveBio, New York, NY, USA

ABSTRACT

GWAS have identified numerous SNPs associated with prostate cancer risk. One such SNP is rs10993994. It is located in the *MSMB* promoter, associates with *MSMB* encoded β-microseminoprotein prostate secretion levels, and is associated with mRNA expression changes in *MSMB* and the adjacent gene *NCOA4.* In addition, our previous work showed a second SNP, rs7098889, is in LD with rs10993994 and associated with *MSMB* expression independent of rs10993994. Here, we generate a series of clones with single alleles removed by double guide RNA (gRNA) mediated CRISPR/Cas9 deletions. We demonstrate that each of these SNPs independently and greatly alters *MSMB* expression in an allele-specific manner. We further show that these SNPs have no substantial effect on the expression of *NCOA4.* These data demonstrate that a single SNP can have a large effect on gene expression and illustrate the importance of functional validation to deconvolute observed correlations. The method we have developed is generally applicable to test any SNP for which a relevant heterozygous cell line is available.

INTRODUCTION

Though genome wide association studies (GWAS) have identified numerous genetic polymorphisms associated with increased risk of disease, the function of these variants remains largely unknown. Just as 99% of the human genome is non-coding sequence, the vast majority of GWAS identified risk associated single nucleotide polymorphisms (SNPs), and SNPs with which they are in high linkage disequilibrium (LD), are located within the non-coding region of the genome (1–3). They are enriched in regulatory regions of the genome and may alter regulatory elements and expression of nearby genes based on studies on epigenetics and expression quantitative trait loci (eQTLs)(2–7). Consistent with this, SNPs in regulatory regions appear to be under evolutionary constraint(8). Experimental validation of this hypothesis has been restricted to a few targeted examples(9–19). A recent loss-of-function screen in 501 cancer cell lines revealed that 82% of cancers depend on RNA expression level(20), far exceeding mutations and copy number changes, underscoring the importance to study the role of cancer risk variants in gene expression.

Prostate cancer, the second leading cause of cancer-related death in men in the United States, is a good model to investigate the mechanism through which common variants influence disease risk. Prostate cancer is highly heritable, as evidenced by increased rates of comorbidity among monozygotic twins compared to dizygotic twins(21–23). To date, approximately 100 independent risk SNPs have been identified (24). These variants tend to be associated with gene expression changes in normal prostate tissue, prostate cancer, and prostatic secretions (25–30) and are found more often in prostatic regulatory regions(31, 32). For instance, the prostate cancer risk SNP rs10993994 is located in the promoter of *MSMB*, which encodes β-microseminoprotein (β-MSP), one of the most abundant proteins in prostate secretions. This SNP is associated with changes in the mRNA level of *MSMB* as well as the nearby androgen receptor co-regulator *NCOA4*(25, 30, 33). Levels of β-MSP in

both blood and semen are also associated with this SNP, as are levels of the prostate-secreted proteins prostate-specific antigen (PSA; gene name *KLK3*) and human kallikrein-related peptidase 2 (hK2; gene name *KLK2*)(30). Rs10993994 is in a 33kb LD block, within which we had also found a second SNP, rs7098889, that is associated with β-MSP levels in prostate tissue independent of rs10993994(30).

With the advent of genome editing tools in mammalian cells such as CRISPR/Cas9(34), it is possible to envision testing a large number of loci for their effect on target gene expression and phenotype. Here, we have chosen to use the highly efficient paired gRNA system(34, 35) to delete a candidate regulatory region. This way, in a heterozygote cell line, we can disentangle the effect of each of the two alleles. Here, we apply this system to rs10993994 and rs7098889. We demonstrate that each of these SNPs independently and greatly alters *MSMB* expression in an allele-specific manner. We further show that these SNPs have no substantial effect on the expression of *NCOA4,* nor do they have a direct effect on the prostate secreted proteins hK2 and PSA. These data demonstrate that a single SNP can have a large effect on gene expression and illustrate the importance of functional validation to deconvolute observed correlations. The method we have developed is generally applicable to test any SNP for which a relevant heterozygous cell line is available.

MATERIAL AND METHODS

CRISPR/Cas9 mediated genome editing with paired gRNAs

We designed paired guide RNAs flanking either the rs7098889 (rs7098889-g1 and rs7098889-g4, Supplementary table 1) or the rs10993994 (rs10993994-g4a and rs10993994-g4b, Supplementary table 2) sites with the Broad Institute CRISPR Design tool (crispr.mit.edu). Guide RNAs were chosen based on the best specificity while maintaining a deletion size of around 200bp. Additionally, since rs1099394 is so close to the transcription start site (TSS) of *MSMB*, the downstream flanking gRNA was chosen to preserve the TSS. Each pair of gRNAs were cloned into pSpCas9(BB)-2A-GFP (PX458) (Addgene, Cambridge, MA, Plasmid 48138) and pSpCas9(BB)-2A-Puro (PX459) V2.0 (Addgene, Plasmid 62988) vectors respectively with CRISPR cloning service from Genscript (Piscataway, NJ). The PX458 vector expresses the Cas9 nuclease, upstream gRNA and the EGFP transfection marker, while the PX459 vector expresses the Cas9 nuclease, downstream gRNA and a puromycin selection marker. The combined use of PX458 and PX459 for paired gRNAs transfection provides convenience to both visualize transfection efficiency under a fluorescence microscope and to do post-transfection puromycin drug selection.

Cell culture and transfection

Both the prostate cancer cell line LNCaP (CRL-1740) and the gastric cancer cell line AGS were obtained from ATCC (ATCC, Rockville, MD). The LNCaP cells were cultured in RPMI 1640 medium (Gibco 11875-093, Life Technologies) supplemented with 15% fetal bovine serum (FBS) and the AGS cells were cultured in F12K medium (Gibco 21127-022, Life Technologies) with 10% FBS, both with

the presence of 1% penicillin/streptomycin (Gibco 15140-122, Life Technologies). Cells were kept in standard 37°C, 5% CO_2 incubator. Cells were split the day before transfection and allowed to reach 30-70% confluence on the day of transfection. To generate deletion of the rs7098889 site, 2µg each of PX458-rs7098889-g1 and PX459v2-rs7098889-g4 plasmids were mixed with 250µl Opti-MEM (Gibco 31985-070, Life Technologies), then gently mixed with room temperature 10µl Lipofectmine 2000/250µl Opti-MEM mix. After 20 min incubation at room temperature, the mix was added evenly to cells. Cells were put back in the incubator for 4-6 hours before changing to 37°C warm and fresh medium. As control, the empty vector PX458 and PX459v2 pair were transfected in parallel. 36-48 hours later, transfected GFP positive cells were observed under fluorescent microscopy to ensure successful transfection. Puromycin selection was begun by incubating cells in the presence of 2µg/ml puromycin (Santa Cruz Biotechnology sc-108071). Approximately 3-7 days later, puromycin was reduced to 0.5µg/µl for post-selection cell expansion. For single cell cloning, 1µg of each plasmid was used in transfection to reduce transfection and deletion efficiency.

Genomic PCR and identification of isogenic allelic deletion by Sanger sequencing

Genomic DNA was extracted from bulk transfected LNCaP or AGS cells upon completion of puromycin selection using DNeasy kit (Qiagen, Germany), or from LNCaP single clones derived from the bulk transfections. Deletion was confirmed by PCR amplification using primers flanking the deletion region, rs7098889-For1 and rs7098889-Rev1 for rs7098889 site (Supplementary Table 1, synthesized by Invitrogen); and rs10993994-F1 and rs10993994-R1 (Supplementary Table 2, synthesized by Invitrogen) for rs10993994 site. Touchdown PCR was used (95°C 1 min; 10 cycles of 95°C 15 sec, 68°C -1°C/cycle 15 sec, 72°C 30 sec; 25 cycles of 95°C 15 sec, 60°C 15 sec, 72°C 30 sec; 72°C 5 min, 4°C incubate). PCR products were resolved on 1.5% agarose gel stained by SYBR green and visualized under UV light. Alleles with deletion end up with 178bp band compared to the 369bp no deletion band for rs7098889 deletion; 274bp vs. 479bp for rs10993994 deletion. All bands were excised from the agarose gel, purified by QIAquick Gel Extraction Kit (Qiagen, Germany), and sent for Sanger sequencing (Genewiz) for sequence validation. Only the clones with correct deletion junction and correct wild type sequence were used for further analysis.

Total RNA extraction and real time qPCR analysis

To compare gene expression changes of *MSMB*, *NCOA4*, *KLK2* and *KLK3* from different transfection and isogenic clones, cells were harvested at 60-90% confluence for total RNA extraction with Qiagen RNeasy Mini kit (Qiagen, Hilden, Germany) and quantified by Nanodrop spectrophotometer (ThermoScientific, ND-8000). 1µg extracted RNA were then reverse transcribed into cDNA with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems #4368814). For real time PCR, TaqMan gene-specific primers were ordered from Life Technologies for *MSMB* (Hs00159303_m1), *NCOA4* (Hs01033772_g1), *KLK2* (Hs00428383_m1) and *KLK3* (Hs02576345). GAPDH was used as internal control. qPCR reactions were setup according to the TaqMan Gene Expression Assays protocol and performed on a ViiA7 real time PCR system (Applied Biosystems, Life Technologies). Each sample was amplified in duplicate, average gene expression and standard deviation were

calculated. Relative gene expression was analyzed with the $\Delta\Delta C_T$ method (Applied Biosystems, cms_042380).

Western blot

Cells from six-well plates were collected by cold PBS, whole cell lysate were prepared using cold NP40 buffer (150mM NaCl, 1% Igepal CA630 and 50mM Tris-HCl, pH 8.0) supplemented with Protease Arrest™ (Calbiochem #KP14001, 1:50 dilution). After incubation on ice for 30 minutes and centrifugation for 10 minutes at 12,000 rpm, supernatant was recovered and protein concentrations were measured using the BioRad Protein Assay Dye Reagent (BioRad 500-0006). 50µg protein was pipetted into each lane and separated on a SDS-PAGE gel (Bolt 4-12% Bis-Tris Plus, Invitrogen, Life Technologies) and the Precision Plus Protein Standards (BioRad) was used as molecular weight marker. Transfer was done on Bio-Rad Trans-Blot Turbo Transfer System onto 0.2 um PVDF membrane (BioRad #1704156). After blocking in 5% milk at room temperature for 1 hour, membranes were incubated in primary antibody diluted in TBST buffer with 1% BSA (Sigma #A9647) for overnight at 4°C. Followed by 3 times 10 minutes wash in TBST buffer (10X Bio-Rad TBS plus 0.05% Tween-20), membranes were incubated another hour at room temperature in secondary antibody diluted in 2.5% milk TBST buffer. After final wash, the results were visualized by the Bio-Rad ClarityTM Western ECL substrate (Bio-Rad #170-5061). Antibodies used are: anti-β-MSP (Origene clone 6C7 #TA501072, 1:3000, lot #A01); anti-β-actin (Sigma clone AC-15, #A5441, 1:5000, lot #122M4782); anti-mouse IgG-HRP (ThermoScientific Pierce Antibody #31432, 1:5000).

Immunodetection of β-MSP, hK2 and PSA secretion

All immunoassay measurements of PSA, hK2, and MSP were conducted blinded on the Victor instrument (Perkin-Elmer, Turku, Finland) using the dual-label DELFIA Prostatus® total/free PSA-Assay (Perkin-Elmer, Turku, Finland) calibrated against the World Health Organization (WHO) 96/670 (PSA-WHO) and WHO 68/668 (free PSA-WHO) standards. Production and purification of the polyclonal rabbit anti-MSP antibody, protocols for biotinylation and Europium labeling of the anti-MSP antibody, and performance of the MSP-immunoassay were performed as previously reported (36). Duplicate samples were read, average and standard deviation were plotted.

Single cell cloning

Upon completion of puromycin selection, bulk PX458-rs7098889-g1 and PX459v2-rs7098889-g4 transfected LNCaP cells or the bulk PX458-rs10993994-g4a and PX459v2-rs10993994-g4b transfected LNCaP cells were plated into 96-well plates (Falcon) by serial dilution. Cells were cultured in LNCaP condition medium filtered by 0.22µm Millex membrane (Millipore) until colonies starting form in about 3 weeks. Single clones were then trypsinized and transferred to 24-well plates followed by 6 well plates in triplicates, and used for genomic DNA extraction followed by PCR and Sanger sequencing genotype identification, freezing clones, and future experiments, respectively.

Allelic expression analysis

Total RNA was extracted from bulk transfected LNCaP and validated single clones, followed by reverse transcription (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems #4368814), cDNA then amplified by PCR reaction with primers flanking *MSMB* 360A/T site. Agarose gel purified PCR products were then subjected to Sanger sequencing by Genewiz and returned chromatogram sequence were visualized in 4Peaks.

RESULTS

Rs7098889 is found in the most prostate-specific enhancer

To determine the causal allele(s) for prostate cancer associated risk SNPs we hypothesized that causal variants would likely be present in prostate specific regulatory elements. Using data on active enhancers from the FANTOM5 consortium analysis of enhancer RNAs(5) (http://slidebase.binf.ku.dk/human_enhancers/selector), we found that the most prostate specific enhancer is located 5kb upstream of the *MSMB* promoter and overlaps rs7098889 (Table 1; Figure 1).

CRISPR/Cas9 mediated deletion of the region flanking rs7098889 leads to significant increase of MSMB expression

We therefore used paired gRNA mediated CRISPR/Cas9 deletion to remove the 191bp region flanking rs7098889 in two heterozygous cell lines -- LNCaP (prostate cancer) and AGS (gastric cancer) (Fig. 2A and Fig.2B). Efficient deletion of the region was confirmed by genomic PCR (Fig. 2B), though we noted another variant (rs4304716, r^2=0.87 with rs7098889) in this deletion region as well. We next examined gene expression levels in these bulk transfected cells and found that *MSMB* exhibited 9.5-fold overexpression after deletion of this regulatory region in LNCaP, but not in AGS (Fig. 2C). In contrast, *NCOA4*, whose expression is associated with rs10993994 and rs7098889 in GTEx eQTL data(7), was not significantly altered after deletion. Similarly, neither *KLK2* (codes for hK2) nor *KLK3* (codes for PSA) levels were altered after deleting this element (Supplementary Fig. 1 and 2). The over-expressed transcripts were translated into β-MSP protein and secreted from LNCaP (Fig. 2D and Fig.2E). We observed similar results at the mRNA level for *MSMB* and *NCOA4* in RWPE-1, a virally transformed prostate cell line (Supplementary Figure 4), and VCaP, another prostate cancer cell line (Supplementary Figure 5). These data suggest that rs7098889 is located at a regulatory region that strongly and specifically regulates *MSMB* expression in prostate tissue.

Rs7098889 T allele, but not the C allele, confers about 300-fold increase of *MSMB* expression

We next generated single-cell clones from the transfected cells and identified derivative lines that have each of the possible genotypes – del/del, del/T, and del/C – by titrating the transfected plasmids expressing gRNAs/Cas9 to reduce efficiency and increase the chance of getting heterozygous clones (Fig. 3A and Fig. 2B). Again, in the bulk transfected cells there is a dramatic increase in *MSMB* expression (Fig. 3C). Sub-cloning of these cells followed by Sanger sequencing (Supplementary File 1) confirmed three T clones (T/del for clone 3, 4, 5), two C clones (C/del for clone 6, 7), as well as two

clones with homozygous deletion (del/del for clone 1, 2). Since LNCaP is aneuploid, we also included the upper bands for genotyping to ensure no additional copies of the intended target allele remained. Surprisingly, for every single clone we analyzed, the remaining alleles were always identical (either T or C) at locus rs7098889 (Supplementary File 1).

Two out of three of the T clones (clones 4, 5) express MSMB close to 300 fold higher than baseline (Fig. 3C), while no overexpression is observed in the C clones (clones 6, 7). In the case of the double deletion, one of the two clones overexpressed *MSMB*. To the best of our knowledge, this is the first example of a GWAS-identified risk SNP that unequivocally shows such dramatic effect on gene expression in a highly tissue specific manner. Notably, this effect is very specific to *MSMB* expression alone, as no significant change in adjacent *NCOA4* expression is observed, nor is a trans effect on expression of *KLK2* or *KLK3* present (supplementary Fig. 2).

Allele specific expression of *MSMB* in LNCaP cells

A single nucleotide variant (SNV) 360A/T unique to and heterozygous in LNCaP was identified by Sanger sequencing in the last exon of *MSMB*. We used this SNV as a marker to trace allelic origin of the transcripts. Overexpressed *MSMB* transcripts from all *MSMB* high expression clones (clones 2, 4, 5) and the bulk LNCaP cells all came from the 360T allele (Fig. 4B). The control LNCaP parental cells and the empty vector control only express very low basal level of *MSMB*. In these cases, the transcripts come from both alleles (Fig. 4B, 360A/T)

Rs10993994 C allele, but not the T risk allele, also confers significant *MSMB* over-expression

Previous work at this locus suggested that rs10993994 may be the causal SNP for prostate cancer risk as it localizes in the promoter region of *MSMB* and alters the ability of the promoter to drive expression in a reporter assay(33, 37). Thus, we performed a similar CRISPR/Cas9 mediated genome editing experiment to validate its role in the regulation of *MSMB* gene expression (Fig. 5A). We deleted a 205bp region flanking rs10993994. In the bulk transfected LNCaP cells, this deletion results in 2.8 fold overexpression of *MSMB* (Fig. 5B). No overexpression was observed either in the gastric cancer AGS cell line or of the immediate downstream NCOA4 gene (Fig. 5B). As with rs7098889, introducing this deletion into both RWPE-1 and VCaP results in a similar overexpression of *MSMB* (Supplementary Fig. 4-5). Single cell clones were then generated from the bulk transfected LNCaP cells and resulted in three heterozygous clones with the C allele deletion (T/del for clone 2, 3, 4); three heterozygous clones with T allele deletion (C/del for clone 5, 6, 7); and one clone with homozygous deletion (del/del for clone 1). Even though the deletion removed the majority of the *MSMB* promoter including the TATA box (Supplementary File 2), significant overexpression of *MSMB* was observed in two of the three C/del clones (Fig. 5C), potentially by transcription from an alternate promoter. Such overexpression was not observed in any of the T/del or del/del clones. Also, we did not observe substantial change of *NCOA4, KLK3* and *KLK2* gene expression in any of these clones (Supplementary Fig. 3). The result suggests the existence of a strong transcription repression mechanism mediated through both the rs7098889 and the rs10993994 loci. Furthermore, the fact that

both loci have dramatic effects on *MSMB* expression in prostate tissue supports the hypothesis that the association of these SNPs with prostate cancer risk is mediated through their regulation of *MSMB* gene expression.

DISCUSSION

Here, we have unequivocally demonstrated dramatic allelic effects on *MSMB* expression at two prostate-cancer associated SNPs. Notably, despite these two SNPs being in strong linkage disequilibrium in European populations, each SNP appears to independently influence *MSMB* expression. One can imagine a model in which it is the set of alleles on a haplotype, each exerting an effect, that leads to the observed phenotype rather than the typically assumed model in which there is a single causal allele in LD with other SNPs. Consistent with this hypothesis, reporter assays based on phenotype-associated human haplotypes have demonstrated such additive effects as well(38).

Previous correlative work had implicated both *MSMB* and *NCOA4* as target genes of rs10993994 and potential mediators of the SNP's effect on prostate cancer risk(25), though studies of protein expression found that rs10993994 is only associated with β-MSP, and not NCOA4, expression(39). Our results demonstrate that regulatory regions encompassing both rs10993994 and rs7098889 directly affect the levels of *MSMB* only and have no effect on *NCOA4*. *MSMB* codes for β-MSP, a major secretory product of the prostate. It is widely secreted by multiple mucosal tissues(40) and has been proposed to manifest both fungicidal activity(41) and tumor suppressive properties(25, 42, 43). The levels of β-MSP in blood are negatively correlated with risk of a prostate cancer diagnosis(44) and positively associated with recurrence-free survival (45). These findings are consistent with a direct role for *MSMB* in prostate cancer etiology. However, we cannot exclude a potential role for *NCOA4*, mediated by previously unidentified SNPs in LD with rs10993994, either instead of or in addition to *MSMB*.

The number of GWAS loci for which causal variants and their downstream effect have been identified using genome editing is relatively limited(9, 11, 12, 14–19, 46). One limiting factor is that in many cases, genome editing revealed that the allelic effect on target gene expression is very mild. In contrast, here we have shown extensive overexpression conferred by altering SNP-containing regulatory regions. Second, the low efficiency of homology-directed repair limits large-scale application of CRISPR/Cas9. Our alternative approach of using a paired gRNA system(34, 35) to delete single copies of heterozygous alleles allows us to observe the effect of each variant allele in isolation.

As GWAS have identified numerous genetic polymorphisms associated with increased risk of cancer and other diseases, the next big challenge is to understand how they mediate pathogenesis, especially for regulatory variants. The majority of these variants are found in the non-coding region of the genome(1–3) and enriched in regulatory regions identified by large-scale functional genomics projects including ENCODE, Roadmap Epigenome and FANTOM5(2–6). These observations together with a recent report that 82% of cancers depend on RNA expression level(20) changes

indicate the importance of studying the relationship between disease risk variants and gene expression. Our study for the first time demonstrates dramatic cell-specific and gene-specific effect on gene expression mediated by GWAS-identified risk variants and provides an efficient way for further systematic study of the function of other GWAS variants.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR online.

DATA AVAILABILITY

Cell clones generated in the study are available upon request. Contact: Robert J Klein robert.klein@mssm.edu

FUNDING

This work was supported by the National Institutes of Health [U01 HG007033, R01 CA175491 to R.J.K.,P30 CA008748, P50 CA092629 to H.G.L.]; the Sidney Kimmel Center for Prostate and Urologic Cancers; David H. Koch through the Prostate Cancer Foundation; Oxford Biomedical Research Centre Programme; the Swedish Cancer Society [CAN 2017/559];, and the Swedish Research Council [VR-MH project no. 2016-02974]. Funding for open access charge: National Institutes of Health R01 CA175491.

CONFLICT OF INTEREST

Xing Xu is an employee and shareholder of SolveBio. Hans Lilja holds patents for free PSA, hK2, and intact PSA assays, and a patent for a statistical method to detect prostate cancer. The marker assay patents and the patent for the statistical model has been licensed and commercialized as the 4K score by OPKO Diagnostics. Dr. Lilja receives royalties from sales of this test and owns stock in OPKO.

REFERENCES

1. Manolio,T.A. (2010) Genomewide Association Studies and Assessment of the Risk of Disease. *N. Engl. J. Med.*, **363**, 166–176.
2. Maurano,M.T., Humbert,R., Rynes,E., Thurman,R.E., Haugen,E., Wang,H., Reynolds,A.P., Sandstrom,R., Qu,H., Brody,J., *et al.* (2012) Systematic localization of common disease-associated variation in regulatory DNA. *Science (80-.).*, **337**, 1190–1195.
3. Encode Project Consortium, Dunham,I., Kundaje,A., Aldred,S.F., Collins,P.J., Davis,C.A., Doyle,F., Epstein,C.B., Frietze,S., Harrow,J., *et al.* (2012) An integrated encyclopedia of DNA elements in the human genome. *Nature*, **489**, 57–74.
4. Roadmap Epigenomics Consortium, Kundaje,A., Meuleman,W., Ernst,J., Bilenky,M., Yen,A., Heravi-Moussavi,A., Kheradpour,P., Zhang,Z., Wang,J., *et al.* (2015) Integrative analysis of 111

reference human epigenomes. *Nature*, **518**, 317–330.

5. Andersson,R., Gebhard,C., Miguel-Escalada,I., Hoof,I., Bornholdt,J., Boyd,M., Chen,Y., Zhao,X., Schmidl,C., Suzuki,T., *et al.* (2014) An atlas of active enhancers across human cell types and tissues. *Nature*, **507**, 455–461.
6. Price,A.L., Spencer,C.C.A. and Donnelly,P. (2015) Progress and promise in understanding the genetic basis of common diseases. *Proceedings. Biol. Sci.*, **282**, 20151684.
7. Ardlie,K.G., Deluca,D.S., Segre,A. V., Sullivan,T.J., Young,T.R., Gelfand,E.T., Trowbridge,C.A., Maller,J.B., Tukiainen,T., Lek,M., *et al.* (2015) The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science (80-.).*, **348**, 648–660.
8. Levenstien,M.A. and Klein,R.J. (2011) Predicting functionally important SNP classes based on negative selection. *BMC Bioinformatics*, **12**, 26.
9. Yao,L., Tak,Y.G., Berman,B.P. and Farnham,P.J. (2014) Functional annotation of colon cancer risk SNPs. *Nat Commun*, **5**, 5114.
10. Claussnitzer,M., Dankel,S.N., Kim,K.-H., Quon,G., Meuleman,W., Haugen,C., Glunk,V., Sousa,I.S., Beaudry,J.L., Puviindran,V., *et al.* (2015) FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. *N. Engl. J. Med.*, **373**, 895–907.
11. Grampp,S., Platt,J.L., Lauer,V., Salama,R., Kranz,F., Neumann,V.K., Wach,S., Stöhr,C., Hartmann,A., Eckardt,K.-U., *et al.* (2016) Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer. *Nat. Commun.*, **7**, 13183.
12. Spisak,S., Lawrenson,K., Fu,Y., Csabai,I., Cottman,R.T., Seo,J.H., Haiman,C., Han,Y., Lenci,R., Li,Q., *et al.* (2015) CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants. *Nat. Med.*, **21**, 1357–1363.
13. Tak,Y.G., Hung,Y., Yao,L., Grimmer,M.R., Do,A., Bhakta,M.S., O'Geen,H., Segal,D.J. and Farnham,P.J. (2016) Effects on the transcriptome upon deletion of a distal element cannot be predicted by the size of the H3K27Ac peak in human cells. *Nucleic Acids Res.*, **44**, 4123–4133.
14. Won,H., de la Torre-Ubieta,L., Stein,J.L., Parikshak,N.N., Huang,J., Opland,C.K., Gandal,M.J., Sutton,G.J., Hormozdiari,F., Lu,D., *et al.* (2016) Chromosome conformation elucidates regulatory relationships in developing human brain. *Nature*, **538**, 523–527.
15. Jin,H.-J., Jung,S., DebRoy,A.R. and Davuluri,R. V (2016) Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer. *Oncotarget*, **7**, 54616–54626.
16. Fulco,C.P., Munschauer,M., Anyoha,R., Munson,G., Grossman,S.R., Perez,E.M., Kane,M., Cleary,B., Lander,E.S. and Engreitz,J.M. (2016) Systematic mapping of functional enhancer-promoter connections with CRISPR interference. *Science*, **354**, 769–773.
17. Liu,H., Leslie,E.J., Carlson,J.C., Beaty,T.H., Marazita,M.L., Lidral,A.C. and Cornell,R.A. (2017) Identification of common non-coding variants at 1p22 that are functional for non-syndromic orofacial clefting. *Nat. Commun.*, **8**, 14759.
18. Soldner,F., Stelzer,Y., Shivalila,C.S., Abraham,B.J., Latourelle,J.C., Barrasa,M.I., Goldmann,J., Myers,R.H., Young,R.A. and Jaenisch,R. (2016) Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression. *Nature*, **533**, 95–99.

19. Maharry,S.E., Walker,C.J., Liyanarachchi,S., Mehta,S., Patel,M., Bainazar,M.A., Huang,X., Lankenau,M.A., Hoag,K.W., Ranganathan,P., *et al.* (2016) Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia. *Cancer Discov.*, **6**, 1036–1051.
20. Tsherniak,A., Vazquez,F., Montgomery,P.G., Weir,B.A., Kryukov,G., Cowley,G.S., Gill,S., Harrington,W.F., Pantel,S., Krill-Burger,J.M., *et al.* (2017) Defining a Cancer Dependency Map. *Cell*, **170**, 564–576.e16.
21. Grönberg,H., Damber,L. and Damber,J.E. (1994) Studies of genetic factors in prostate cancer in a twin population. *J. Urol.*, **152**, 1484-7; discussion 1487-9.
22. Lichtenstein,P., Holm,N. V., Verkasalo,P.K., Iliadou,A., Kaprio,J., Koskenvuo,M., Pukkala,E., Skytthe,A. and Hemminki,K. (2000) Environmental and Heritable Factors in the Causation of Cancer — Analyses of Cohorts of Twins from Sweden, Denmark, and Finland. *N. Engl. J. Med.*, **343**, 78–85.
23. Mucci,L.A., Hjelmborg,J.B., Harris,J.R., Czene,K., Havelick,D.J., Scheike,T., Graff,R.E., Holst,K., Möller,S., Unger,R.H., *et al.* (2016) Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. *JAMA*, **315**, 68.
24. Al Olama,A.A., Kote-Jarai,Z., Berndt,S.I., Conti,D. V, Schumacher,F., Han,Y., Benlloch,S., Hazelett,D.J., Wang,Z., Saunders,E., *et al.* (2014) A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. *Nat Genet*, **46**, 1103–1109.
25. Pomerantz,M.M., Shrestha,Y., Flavin,R.J., Regan,M.M., Penney,K.L., Mucci,L.A., Stampfer,M.J., Hunter,D.J., Chanock,S.J., Schafer,E.J., *et al.* (2010) Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. *PLoS Genet*, **6**, e1001204.
26. Grisanzio,C., Werner,L., Takeda,D., Awoyemi,B.C., Pomerantz,M.M., Yamada,H., Sooriakumaran,P., Robinson,B.D., Leung,R., Schinzel,A.C., *et al.* (2012) Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. *Proc Natl Acad Sci U S A*, **109**, 11252–11257.
27. Penney,K.L., Sinnott,J.A., Tyekucheva,S., Gerke,T., Shui,I.M., Kraft,P., Sesso,H.D., Freedman,M.L., Loda,M., Mucci,L.A., *et al.* (2015) Association of prostate cancer risk variants with gene expression in normal and tumor tissue. *Cancer Epidemiol Biomarkers Prev*, **24**, 255–260.
28. Xu,X., Hussain,W.M., Vijai,J., Offit,K., Rubin,M.A., Demichelis,F. and Klein,R.J. (2014) Variants at IRX4 as prostate cancer expression quantitative trait loci. *Eur J Hum Genet*, **22**, 558–563.
29. Savblom,C., Hallden,C., Cronin,A.M., Sall,T., Savage,C., Vertosick,E.A., Klein,R.J., Giwercman,A. and Lilja,H. (2014) Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men. *Clin Chem*, **60**, 490–499.
30. Xu,X., Valtonen-André,C., Sävblom,C., Halldén,C., Lilja,H. and Klein,R.J. (2010) Polymorphisms at the microseminoprotein-?? locus associated with physiologic variation in □??-microseminoprotein and prostate-specific antigen levels. *Cancer Epidemiol. Biomarkers Prev.*, **19**, 2035–2042.
31. Gusev,A., Shi,H., Kichaev,G., Pomerantz,M., Li,F., Long,H.W., Ingles,S.A., Kittles,R.A.,

Strom,S.S., Rybicki,B.A., *et al.* (2016) Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. *Nat Commun*, **7**, 10979.

32. Whitington,T., Gao,P., Song,W., Ross-Adams,H., Lamb,A.D., Yang,Y., Svezia,I., Klevebring,D., Mills,I.G., Karlsson,R., *et al.* (2016) Gene regulatory mechanisms underpinning prostate cancer susceptibility. *Nat Genet*, **48**, 387–397.
33. Lou,H., Yeager,M., Li,H., Bosquet,J.G., Hayes,R.B., Orr,N., Yu,K., Hutchinson,A., Jacobs,K.B., Kraft,P., *et al.* (2009) Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. *Proc. Natl. Acad. Sci.*, **106**, 7933–7938.
34. Ran,F.A., Hsu,P.D., Wright,J., Agarwala,V., Scott,D.A. and Zhang,F. (2013) Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.*, **8**, 2281–308.
35. Zheng,Q., Cai,X., Tan,M.H., Schaffert,S., Arnold,C.P., Gong,X., Chen,C.-Z. and Huang,S. (2014) Precise gene deletion and replacement using the CRISPR/Cas9 system in human cells. *Biotechniques*, **57**, 115–24.
36. Haiman,C.A., Stram,D.O., Vickers,A.J., Wilkens,L.R., Braun,K., Valtonen-André,C., Peltola,M., Pettersson,K., Waters,K.M., Marchand,L. Le, *et al.* (2013) Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations. *J. Natl. Cancer Inst.*, **105**, 237–43.
37. Chang,B.-L., Cramer,S.D., Wiklund,F., Isaacs,S.D., Stevens,V.L., Sun,J., Smith,S., Pruett,K., Romero,L.M., Wiley,K.E., *et al.* (2009) Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. *Hum. Mol. Genet.*, **18**, 1368–1375.
38. Guo,C., Ludvik,A.E., Arlotto,M.E., Hayes,M.G., Armstrong,L.L., Scholtens,D.M., Brown,C.D., Newgard,C.B., Becker,T.C., Layden,B.T., *et al.* (2015) Coordinated regulatory variation associated with gestational hyperglycaemia regulates expression of the novel hexokinase HKDC1. *Nat. Commun.*, **6**, 6069.
39. FitzGerald,L.M., Zhang,X., Kolb,S., Kwon,E.M., Liew,Y.C., Hurtado-Coll,A., Knudsen,B.S., Ostrander,E.A. and Stanford,J.L. (2013) Investigation of the Relationship Between Prostate Cancer and MSMB and NCOA4 Genetic Variants and Protein Expression. *Hum. Mutat.*, **34**, 149–156.
40. Weiber,H., Andersson,C., Murne,A., Rannevik,G., Lindström,C., Lilja,H. and Fernlund,P. (1990) Beta microseminoprotein is not a prostate-specific protein. Its identification in mucous glands and secretions. *Am. J. Pathol.*, **137**, 593–603.
41. Edström Hägerwall,A.M.L., Rydengård,V., Fernlund,P., Mörgelin,M., Baumgarten,M., Cole,A.M., Malmsten,M., Kragelund,B.B. and Sørensen,O.E. (2012) β-Microseminoprotein Endows Post Coital Seminal Plasma with Potent Candidacidal Activity by a Calcium- and pH-Dependent Mechanism. *PLoS Pathog.*, **8**, e1002625.
42. Garde,S., Sheth,A., Porter,A.T. and Pienta,K.J. (1993) Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo. *Prostate*, **22**, 225–33.
43. Lokeshwar,B.L., Hurkadli,K.S., Sheth,A.R. and Block,N.L. (1993) Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic

adenocarcinoma, the Dunning R3327G rat tumor. *Cancer Res.*, **53**, 4855–9.
44. Whitaker,H.C., Kote-Jarai,Z., Ross-Adams,H., Warren,A.Y., Burge,J., George,A., Bancroft,E., Jhavar,S., Leongamornlert,D., Tymrakiewicz,M., *et al.* (2010) The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. *PLoS One*, **5**, e13363.
45. Bjartell,A.S., Al-Ahmadie,H., Serio,A.M., Eastham,J.A., Eggener,S.E., Fine,S.W., Udby,L., Gerald,W.L., Vickers,A.J., Lilja,H., *et al.* (2007) Association of Cysteine-Rich Secretory Protein 3 and -Microseminoprotein with Outcome after Radical Prostatectomy. *Clin. Cancer Res.*, **13**, 4130–4138.
46. Claussnitzer,M., Dankel,S.N., Kim,K.-H., Quon,G., Meuleman,W., Haugen,C., Glunk,V., Sousa,I.S., Beaudry,J.L., Puviindran,V., *et al.* (2015) *FTO* Obesity Variant Circuitry and Adipocyte Browning in Humans. *N. Engl. J. Med.*, **373**, 895–907.

TABLE AND FIGURES LEGENDS

Table 1. Top 10 prostate specific enhancers defined by eRNA expression in the FANTOM5 project. Rs7098889 is positioned at chr10:51544475.

Figure 1. Position of prostate-specific enhancer chr10:51544405-51544819 defined by FANTOM5 project.

Figure 2. CRISPR/Cas9 mediated deletion of 191bp region flanking rs7098889 confers significant increase of *MSMB* expression. (**A**) Sanger sequencing showed both LNCaP and AGS cells are heterozygous (C/T) at rs7098889 site. (**B**) CRISPR/Cas9 mediated rs7098889 deletion was created by paired guide RNAs (rs7098889-g1 and -g4) transfection followed by puromycin selection. The deletion was confirmed by PCR amplification with primer pair (rs7098889-For1 and -Rev1) flanking the deleted region, PCR product runs at 178bp on agarose gel with deletion, and at 369bp without deletion. (**C**) Real time qPCR showed 9.5 folds *MSMB* over-expression in prostate cancer LNCaP cells with bulk transfection but not the gastric cancer AGS cells. The expression of downstream *NCOA4* gene is barely affected. (**D**) Western blot showed that the *MSMB* protein product β-MSP is significantly up-regulated in LNCaP cells with deletion, but not in AGS cells. (**E**) ELISA assay showed that the secreting β-MSP level significantly up-regulated in LNCaP cells with deletion either in the presence (28.0 ng/ml) or absence (2.8ng/ml) of FBS in cell culture.

Figure 3. Single clone screening of LNCaP cells with rs7098889 deletion reveals allelic differential and even more dramatic *MSMB* over-expression. (**A**) Transfection titration generated LNCaP bulk cells with lower deletion efficiency for better isolating heterozygous single clones. (**B**) Illustration of single clone genotypes with homozygous (del/del) and heterozygous deletion (T/del and C/del). (**C**) Real time qPCR showed dramatic MSMB over-expression (262 and 286 folds) in two (clone 4, 5) out of three clones with rs7098889 T allele (clone 3, 4, 5) but not the C allele (clone 6, 7). Bulk deletion

with lower deletion efficiency, thus more heterozygous alleles, generates 15 folds over-expression (lane 3) compared to 9.55 folds from previous experiment (Fig. 1**C**).

Figure 4. Allelic expression of *MSMB* in LNCaP cells. (**A**) Demonstration of 360A/T single nucleotide variant (SNV) located in the last exon of *MSMB* gene. (**B**) Transcripts from all the MSMB high expressing clones (clone 2, 4, 5) and the LNCaP bulk deletion came from the 360T allele examined by PCR followed by Sanger sequencing of the last exon of MSMB gene flanking the 360A/T heterozygous site.

Figure 5. CRISPR/Cas9 mediated deletion of 205bp rs10993994 flanking region confers significant increase of *MSMB* expression. (**A**) Paired gRNA (rs10993994-g4a and –g4b) mediated CRISPR/Cas9 deletion of rs10993994 region was confirmed by PCR amplification with flanking primer pair rs10993994-F1 and –R1. PCR product runs at 274bp on agarose gel with deletion, and at 479bp without deletion. (**B**) Real time qPCR showed 2.8 folds *MSMB* over-expression in prostate cancer LNCaP cells with bulk deletion but not in the gastric cancer AGS cells. The expression of downstream *NCOA4* gene is down-regulated. (**C**) Real time qPCR of single clones generated from above bulk transfection. MSMB over-expression was seen in two (clone 5, 6) out of the three clones (clone 4, 5, 6) with rs10993994 C allele (C/del) but not the T allele (T/del, clone 2, 3, 4).


Scale
chr10:
10 kb
hg19
51,545,000
51,550,000
51,555,000
51,560,000
chr10:51544405-51544819 enhancer
Enhancer Track
Chromosome Bands Localized by FISH Mapping Clones
Chromosome Band
10q11.23
RefSeq Genes
TIMM23B
TIMM23B
TIMM23B
TIMM23B
MSMB
MSMB
Simple Nucleotide Polymorphisms (dbSNP 147) Found in >= 1% of Samples
rs4306255
rs7477953
rs73318175
rs4351762
rs75814386
rs10994385
rs7904463
rs16914420
rs6481462
rs7075697
rs111682261
rs7076948
rs4329630
rs11006462
rs73318177
rs60241187
rs7094791
rs7070301
rs112792343
rs10993994
rs4631830
rs34073986
rs143402529
rs7075009
rs7098889
rs4304716
rs72077188

Figure 1


A
150
160
170
ACCCCACCGATCTTGGTGTTAAAT
LNCaP
C/T
AGS
B
LNCaP
AGS
100bp ladder
parental ctrl
vector ctrl
deletion
-369bp
-178bp
Cas9
MSMB
w.t.
-g1
-g4
rs7098889
10993994
rs7098889-For1
rs7098889-Rev1
w.t. alleles
alleles w/ deletions
C
LNCaP
AGS
Relative mRNA expression
10.00
1.00
0.10
9.55
1.00
1.18
0.95
0.71
0.70
0.43
1.02
0.69
par
vec
del
MSMB
NCOA4
D
-β-MSP
-β-actin
AGS
LNCaP exp1
LNCaP exp2
E
β-MSP (ng/ml) in LNCaP
w/o FBS
w/ FBS
Deletion
Vector
Parental
2.8
0.0
28.0
0.3
0.1
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0

Figure 2


A
100bp ladder
vector ctrl
Empty lane
deletion
100bp ladder
-369bp
-178bp
LNCaP
B
del/del
C
T
rs7098889
10993994
T/del
T
C
T
rs7098889
10993994
C/del
C
C
T
rs7098889
10993994
C
LNCaP bulk transfection and single clones
MSMB
Relative mRNA expression level
1000.00
100.00
10.00
1.00
0.10
0.76
1.00
15.24
1.31
157.54
1.37
286.67
262.66
1.49
0.44
parental
vector
deletion
1
2
3
4
5
6
7
bulk
del/del
T/del
C/del

Figure 3


A
360A → T SNV in LNCaP
GTTCTGTCAGTGAATGGATA
MSMB
NM_002443.3_MSMB
B
LNCaP parental ctrl
LNCaP vector control
LNCaP bulk deletion
A/T
A/T
T
Clone 4
Clone 5
Clone 2
T
T
T

Figure 4


A
100bp ladder
parental
vector ctrl
deletion
parental
vector ctrl
deletion
-479bp
-274bp
LNCaP
AGS
w.t.
Cas9
MSMB
rs10993994-g4a
-g4b
rs10993994-F1
-R1
rs7098889
10993994
w.t. alleles
alleles w/ deletions
B
LNCaP
AGS
Relative mRNA expression
par
vec
del
MSMB
NCOA4
C
LNCaP bulk transfection and single clcones
MSMB
bulk
del/del
T/del
C/del
del/del
T/del
C/del

Figure 5